Upotreba nesteroidnih protuupalnih lijekova i rizik od Parkinsonove bolesti: meta-analiza doze i odgovora.
Medicine
Sažetak istraživanja
Prethodne studije su pokazale da je upotreba nesteroidnih antiinflamatornih lekova (NSAID) povezana sa rizikom od Parkinsonove bolesti, ali su dale kontroverzne rezultate. Medline, Embase, Web of Science i Cochrane baza podataka su pretražene ažurirano do novembra 2017. Ključni podaci su izvučeni iz podobnih studija. Provedena je meta-analiza doza-odgovor za sintezu podataka iz podobnih studija. Petnaest prihvatljivih studija je uključeno u ovu meta-analizu. Upotreba NSAIL nije povezana sa rizikom od Parkinsonove bolesti [relevantni rizik (RR): 0,06; 95% interval pouzdanosti (95% CI), 0,91-1,02]. Analiza podgrupe je pokazala da upotreba aspirina (RR: 1,14; 95% CI, 0,98-1,30) ili upotreba ibuprofena (RR: 1,01; 95% CI, 0,88-1,17) nije povezana sa rizikom od Parkinsonove bolesti; međutim, upotreba neaspirinskih NSAIL bila je značajno povezana sa rizikom od Parkinsonove bolesti (RR:0,91; 95% CI, 0,84-0,99). Nadalje, upotreba NSAIL nije povezana sa rizikom od Parkinsonove bolesti kod žena (RR: 0,99; 95% CI, 0,83-1,17) i muškaraca (RR: 1,01; 95% CI, 0,88-1,16). Osim toga, doza-odgovor prikazan na 1 broj recepta, inkrementalno povećanje upotrebe NSAIL nije povezano s rizikom od Parkinsonove bolesti (RR: 0,96; 95% CI, 0,91-1,02), za godinu dana trajanja upotrebe NSAIL inkrementalno povećanje nije povezano s rizikom od Parkinsonove bolesti.9% CI: 98; 0,92-1,03), a po 1 dozi upotrebe NSAIL inkrementalno povećanje nije bilo povezano sa rizikom od Parkinsonove bolesti (RR: 0,98; 95% CI, 0,95-1,02). Upotreba NSAIL nije bila povezana sa rizikom od Parkinsonove bolesti. Potentnost i kumulativna upotreba NSAIL-a nisu igrali kritičnu ulogu.
Prikaži originalni naslov i sažetak na engleskom
Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis.
Previous studies have indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) use is associated with Parkinson disease risk, but presented controversial results.Medline, Embase, Web of Science, and the Cochrane Database were searched update to November 2017. Key data were extracted from eligible studies. A dose-response meta-analysis was conducted for synthesizing data from eligible studies.Fifteen eligible studies were included in this meta-analysis. NSAIDs use was not associated with Parkinson disease risk [relevant risk (RR): 0.06; 95% confidence interval (95% CI), 0.91-1.02]. Subgroup analysis showed that aspirin use (RR: 1.14; 95% CI, 0.98-1.30) or ibuprofen use (RR: 1.01; 95% CI, 0.88-1.17) was not associated with Parkinson disease risk; however, the use of non-aspirin NSAIDs was significantly associated with Parkinson disease risk (RR:0.91; 95% CI, 0.84-0.99). Furthermore, NSAIDs use was not associated with the risk of Parkinson disease in female (RR: 0.99; 95% CI, 0.83-1.17) and male (RR: 1.01; 95% CI, 0.88-1.16). In addition, a dose-response showed per 1 number of prescription incremental increase in NSAIDs use was not associated with the risk of Parkinson disease (RR: 0.96; 95% CI, 0.91-1.02), per 1 year of duration of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.92-1.03), and per 1 dosage of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.95-1.02).NSAIDs use was not associated with the risk of Parkinson disease. The potency and the cumulative NSAIDs use did not play critical roles.
Izvorni podaci
- DOI
- 10.1097/md.0000000000012172
- PMID
- 30212946
- PMCID
- PMC6155958
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom